Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%
Conditions
Interventions
BNT116
Cemiplimab
Locations
52
United States
The Oncology Institute of Hope and Innovation
Los Angeles, California, United States
UCLA Medical Center
Santa Monica, California, United States
Norton Cancer Institute, Downtown
Louisville, Kentucky, United States
San Juan Oncology Associates
Farmington, New Mexico, United States
Weill Cornell Medicine
New York, New York, United States
FirstHealth of the Carolinas Outpatient Cancer Center
Pinehurst, North Carolina, United States
Start Date
April 21, 2023
Primary Completion Date
January 26, 2028
Completion Date
May 16, 2028
Last Updated
August 21, 2025
NCT06731413
NCT07356544
NCT06956001
NCT06706076
NCT07371663
NCT07222566
Lead Sponsor
Regeneron Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions